APOL1 Kidney Disease Clinical Trial
Enrollment Status
- Enrolling
Enrolling Patients
About This Study
Individuals with APOL1-mediated proteinuric kidney disease (AMKD) experience proteinuria and damage to the kidney’s filtration barrier. This study evaluates the safety and efficacy of an investigational medicine to improve renal function, as a potential APOL1 kidney disease treatment. Every study follows a carefully designed protocol under the oversight of experienced healthcare professionals.
Who May Qualify
You may be eligible to participate if you:
- Are between the ages of 10 to 65
- Have been diagnosed with AMKD
- Are currently receiving care in an intensive care or hospital setting
Additional eligibility criteria apply.
What Participation Involves
Participation includes:
- Study related treatments or standard of care
- Regular assessments and monitoring
- Collection of study-related data and samples
All study-related care is provided at no cost to participants.
Why Participate?
By participating in this study, you may help advance medical research and contribute to the development of new treatments for AMKD and future patients.
- NOVA Clinical Research is committed to protecting your privacy and ensuring all clinical research studies are conducted in accordance with ethical guidelines and federal regulations.
Interested in This Study?
Fill out the form below and a member of our research team will contact you.
Speak With Our Team
Have questions about this study or want to learn more?